Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Nutriband Inc. Warrant (NTRBW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/03/2025: NTRBW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
0 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
Analysis of Past Performance
Type Stock | Historic Profit -73.27% | Avg. Invested days 51 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/03/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 1.2 | 52 Weeks Range 0.75 - 5.25 | Updated Date 06/10/2025 |
52 Weeks Range 0.75 - 5.25 | Updated Date 06/10/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.5 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -211.78% |
Management Effectiveness
Return on Assets (TTM) -36.45% | Return on Equity (TTM) -108.02% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 4420276 |
Shares Outstanding - | Shares Floating 4420276 | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
Nutriband Inc. Warrant
Company Overview
History and Background
Nutriband Inc. focuses on transdermal drug delivery technology. While specific founding year and detailed milestones related solely to the *warrant* are not readily available, Nutriband's history is centered around developing abuse-deterrent transdermal patches.
Core Business Areas
- Abuse-Deterrent Transdermal Technology: Development and commercialization of abuse-deterrent transdermal patches, primarily focusing on controlled substances.
Leadership and Structure
Details on the warrant's leadership are not applicable; this relates to Nutriband Inc.'s management team. The structure is related to the terms of the warrant itself (exercise price, expiration date, etc.)
Top Products and Market Share
Key Offerings
- Abuse-Deterrent Transdermal Patches: Nutriband's primary focus is on transdermal patches designed to deter abuse. Specific market share data is difficult to ascertain due to the niche nature of the market. Competitors include companies developing similar abuse-deterrent technologies, such as Collegium Pharmaceutical.
Market Dynamics
Industry Overview
The pharmaceutical industry is constantly evolving, particularly in the areas of pain management and abuse-deterrent formulations. Increasing regulatory pressure and public health concerns drive innovation in this space.
Positioning
Nutriband positions itself as a leader in abuse-deterrent transdermal technology, aiming to provide safer alternatives to traditional pain medications.
Total Addressable Market (TAM)
The TAM for abuse-deterrent opioid formulations is substantial, estimated to be billions of dollars. Nutriband's positioning depends on the regulatory approval and market adoption of its products.
Upturn SWOT Analysis
Strengths
- Proprietary abuse-deterrent technology
- Focus on a growing market need
- Potential for regulatory approval and market exclusivity
Weaknesses
- Limited commercialized products
- Reliance on regulatory approvals
- Competition from larger pharmaceutical companies
Opportunities
- Partnerships with pharmaceutical companies
- Expansion into new therapeutic areas
- Increased regulatory support for abuse-deterrent formulations
Threats
- Failure to obtain regulatory approvals
- Competition from alternative pain management therapies
- Changes in regulatory landscape
Competitors and Market Share
Key Competitors
- COLL
Competitive Landscape
Nutriband's advantage lies in its transdermal abuse-deterrent technology, but it faces competition from larger, more established pharmaceutical companies.
Growth Trajectory and Initiatives
Historical Growth: Growth depends on Nutriband Inc.'s progress and is speculative for a warrant
Future Projections: Future warrant performance is dependent on underlying stock performance and analyst estimates for Nutriband Inc.
Recent Initiatives: Recent Initiatives of Nutriband include its focus on its Aversa patch for pain management and deterring abuse.
Summary
Nutriband is a company specializing in abuse-deterrent transdermal technology, targeting the pain management market. Their success depends on regulatory approvals, market acceptance, and their ability to compete with larger pharmaceutical companies. The key to Nutriband's success will be commercializing its pipeline of abuse-deterrent patches. They need to look out for regulatory hurdles and competition from existing and new entrants to the market.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Industry Reports
- Analyst Reports
Disclaimers:
This analysis is based on available information and is not financial advice. Warrant prices are highly volatile and can result in a complete loss. Market share data is an estimate.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Nutriband Inc. Warrant
Exchange NASDAQ | Headquaters Orlando, FL, United States | ||
IPO Launch date 2021-10-01 | Founder, CEO & Director Mr. Gareth Sheridan | ||
Sector Healthcare | Industry Biotechnology | Full time employees - | Website https://www.nutriband.com |
Full time employees - | Website https://www.nutriband.com | ||
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products in the United States. The company's lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. It also develops AVERSA buprenorphine and AVERSA methylphenidate, and other transdermal pharmaceutical products. The company has commercial development and clinical supply agreement with Kindeva Drug Delivery. The company was incorporated in 2016 and is headquartered in Orlando, Florida.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.